Passage Bio to Participate in Upcoming Investor Conferences
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company specializing in neurodegenerative diseases, has announced its participation in two major upcoming investor conferences.
The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 9:10 a.m. ET, and the Leerink Global Biopharma Conference in Miami on March 12, 2025, at 8:00 a.m. ET. Both events will feature management presentations and investor meetings.
Interested parties can access live webcasts of the presentations through the Investors & Media section of Passage Bio's website at investors.passagebio.com. Replay recordings will remain available for 30 days after each event.
Passage Bio (NASDAQ: PASG), un'azienda in fase clinica specializzata in medicine genetiche per le malattie neurodegenerative, ha annunciato la sua partecipazione a due importanti conferenze per investitori in programma.
L'azienda presenterà al TD Cowen 45° Annual Health Care Conference a Boston il 5 marzo 2025, alle 9:10 ET, e al Leerink Global Biopharma Conference a Miami il 12 marzo 2025, alle 8:00 ET. Entrambi gli eventi includeranno presentazioni della direzione e incontri con gli investitori.
Le parti interessate possono accedere alle trasmissioni in diretta delle presentazioni attraverso la sezione Investitori e Media del sito web di Passage Bio all'indirizzo investors.passagebio.com. Le registrazioni delle ripetizioni rimarranno disponibili per 30 giorni dopo ciascun evento.
Passage Bio (NASDAQ: PASG), una empresa de medicamentos genéticos en etapa clínica especializada en enfermedades neurodegenerativas, ha anunciado su participación en dos importantes conferencias para inversores que se avecinan.
La empresa presentará en la 45ª Conferencia Anual de Atención Médica de TD Cowen en Boston el 5 de marzo de 2025, a las 9:10 a.m. ET, y en la Conferencia Global de Biofarmacia de Leerink en Miami el 12 de marzo de 2025, a las 8:00 a.m. ET. Ambos eventos incluirán presentaciones de la dirección y reuniones con inversores.
Las partes interesadas pueden acceder a las transmisiones en vivo de las presentaciones a través de la sección de Inversores y Medios del sitio web de Passage Bio en investors.passagebio.com. Las grabaciones de las repeticiones estarán disponibles durante 30 días después de cada evento.
Passage Bio (NASDAQ: PASG), 신경퇴행성 질환을 전문으로 하는 임상 단계 유전자 의약품 회사가 다가오는 두 개의 주요 투자자 회의에 참여한다고 발표했습니다.
회사는 2025년 3월 5일 오전 9시 10분 ET에 보스턴에서 열리는 TD Cowen 제45회 연례 의료 회의와 2025년 3월 12일 오전 8시 ET에 마이애미에서 열리는 Leerink 글로벌 생물제약 회의에서 발표할 예정입니다. 두 이벤트 모두 경영진 발표와 투자자 회의가 포함됩니다.
관심 있는 분들은 Passage Bio 웹사이트의 투자자 및 미디어 섹션을 통해 발표의 실시간 웹캐스트에 접속할 수 있습니다. 각 이벤트 후 30일 동안 재생 녹음이 제공됩니다.
Passage Bio (NASDAQ: PASG), une entreprise de médicaments génétiques en phase clinique spécialisée dans les maladies neurodégénératives, a annoncé sa participation à deux grandes conférences pour investisseurs à venir.
L'entreprise présentera lors de la 45e Conférence Annuelle de Soins de Santé TD Cowen à Boston le 5 mars 2025 à 9h10 ET, et lors de la Conférence Mondiale de Biopharmacie Leerink à Miami le 12 mars 2025 à 8h00 ET. Les deux événements comprendront des présentations de la direction et des réunions avec les investisseurs.
Les parties intéressées peuvent accéder aux diffusions en direct des présentations via la section Investisseurs et Médias du site web de Passage Bio à l'adresse investors.passagebio.com. Les enregistrements des rediffusions seront disponibles pendant 30 jours après chaque événement.
Passage Bio (NASDAQ: PASG), ein Unternehmen für genetische Medikamente in der klinischen Phase, das sich auf neurodegenerative Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei wichtigen bevorstehenden Investorenkonferenzen angekündigt.
Das Unternehmen wird am 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston am 5. März 2025 um 9:10 Uhr ET und an der Leerink Global Biopharma-Konferenz in Miami am 12. März 2025 um 8:00 Uhr ET teilnehmen. Beide Veranstaltungen beinhalten Präsentationen des Managements und Investorenmeetings.
Interessierte Parteien können über den Bereich Investoren & Medien auf der Website von Passage Bio unter investors.passagebio.com auf die Live-Übertragungen der Präsentationen zugreifen. Aufzeichnungen der Wiederholungen sind 30 Tage nach jeder Veranstaltung verfügbar.
- None.
- None.
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
TD Cowen 45th Annual Health Care Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 5, 2025
Presentation Time: 9:10 a.m. ET
Location: Boston, MA
Leerink Global Biopharma Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 12, 2025
Presentation Time: 8:00 a.m. ET
Location: Miami, FL
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com
FAQ
When and where will Passage Bio (PASG) present at the TD Cowen Healthcare Conference 2025?
What is the schedule for PASG's presentation at the Leerink Global Biopharma Conference 2025?
How can investors access Passage Bio's (PASG) conference presentations?
What type of meetings will Passage Bio (PASG) conduct at these conferences?
